

## Engineering the Beating System: Biology Meets Technology

**Company name:** Curespec

**Website:** curespec.info

**CEO name:** Rotem Kaynan

**Category:** Medical Devices

---

### **Executive Summary / Investment Rationale**

Curespec develops Nephrospec™, a non-invasive, kidney-targeted therapy designed to lower blood pressure by addressing underlying renal dysfunction. Hypertension remains the leading global risk factor, with over 50% of patients uncontrolled. The company has demonstrated clinical efficacy and safety across multiple centers and is already generating commercial revenue, positioning it for rapid global scale.

### **Core Technology**

Nephrospec™ utilizes proprietary low-intensity shockwave therapy to restore kidney microcirculation and improve renal function. This approach targets the root cause of hypertension rather than symptoms. The technology is non-invasive, safe, and repeatable, with strong IP protection and validated scientific backing, including studies supported by the Mayo Clinic.

### **Product Profile / Pipeline**

The company's lead product is a CE-marked, non-invasive therapeutic device for hypertension treatment. Clinical data from 74 patients across 5 centers show significant blood pressure reduction with no serious adverse events. The system is already in commercial use with active installations and paying customers across multiple global markets.

### **Business Strategy**

Curespec operates a high-margin model combining device sales and recurring consumables, alongside pay-per-treatment options. With an estimated \$5.9B market opportunity in the US and Europe, the company is scaling through global installations, strategic partnerships, and expansion into high-prevalence regions, leveraging existing Medispec infrastructure.

### **What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans**

The company is advancing toward FDA De Novo approval with a planned U.S. pivotal study. Funding will support clinical expansion, regulatory milestones, manufacturing scale-up, and global commercialization. Curespec is raising \$10M to accelerate growth, strengthen IP, and establish itself as a leading non-invasive solution for hypertension treatment.